Flex Pharma, a biotechnology company developing treatments for neuromuscular disorders, has initiated a Phase II clinical trial of FLX-787 for treating muscle cramps and spasticity in ALS. FLX-787 is a small molecule transient receptor potential (TRP) ion channel activator, which prevents repetitive firing of the spinal motor neurons that control muscle contractions. The randomized, controlled and blinded trial will take place in Australia. Flex Pharma was co-founded by scientific leaders in the area of ion channels, including Roderick MacKinnon of Rockefeller University and Bruce Bean of Harvard Medical School.
Click here to read more.